Cytokeratin 18 Antibody - #AF6849

(1)  
Product: Cytokeratin 18 Antibody
Catalog: AF6849
Description: Rabbit polyclonal antibody to Cytokeratin 18
Application: WB
Reactivity: Human
Mol.Wt.: 51kDa; 48kD(Calculated).
Uniprot: P05783
RRID: AB_2847572

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Polyclonal
Specificity:
Cytokeratin 18 Antibody detects endogenous levels of total Cytokeratin 18.
RRID:
AB_2847572
Cite Format: Affinity Biosciences Cat# AF6849, RRID:AB_2847572.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Cell proliferation inducing gene 46 protein; Cell proliferation inducing protein 46; Cell proliferation-inducing gene 46 protein; CK 18; CK-18; CK18; CYK 18; CYK18; Cytokeratin 18; Cytokeratin endo B; Cytokeratin-18; K 18; K18; K1C18_HUMAN; KA18; Keratin 18; Keratin 18, type I; Keratin D; keratin, type I cytoskeletal 18; Keratin-18; Krt18;

Immunogens

Immunogen:

A synthesized peptide derived from human Cytokeratin 18.

Uniprot:

P05783(K1C18_HUMAN) >>Visit HPA database.

Gene(ID):
KRT18(3875)
Expression:
P05783 K1C18_HUMAN:

Expressed in colon, placenta, liver and very weakly in exocervix. Increased expression observed in lymph nodes of breast carcinoma.

Sequence:
MSFTTRSTFSTNYRSLGSVQAPSYGARPVSSAASVYAGAGGSGSRISVSRSTSFRGGMGSGGLATGIAGGLAGMGGIQNEKETMQSLNDRLASYLDRVRSLETENRRLESKIREHLEKKGPQVRDWSHYFKIIEDLRAQIFANTVDNARIVLQIDNARLAADDFRVKYETELAMRQSVENDIHGLRKVIDDTNITRLQLETEIEALKEELLFMKKNHEEEVKGLQAQIASSGLTVEVDAPKSQDLAKIMADIRAQYDELARKNREELDKYWSQQIEESTTVVTTQSAEVGAAETTLTELRRTVQSLEIDLDSMRNLKASLENSLREVEARYALQMEQLNGILLHLESELAQTRAEGQRQAQEYEALLNIKVKLEAEIATYRRLLEDGEDFNLGDALDSSNSMQTIQKTTTRRIVDGKVVSETNDTKVLRH

PTMs - P05783 As Substrate

Site PTM Type Enzyme
M1 Acetylation
S2 Acetylation
S2 Phosphorylation
T4 Phosphorylation
S7 Phosphorylation
T8 Phosphorylation
S10 Phosphorylation
T11 Phosphorylation
Y13 Phosphorylation
S15 Phosphorylation
S18 Phosphorylation
S23 Phosphorylation
Y24 Phosphorylation
R27 Methylation
S30 O-Glycosylation
S30 Phosphorylation
S31 O-Glycosylation
S31 Phosphorylation
S34 Phosphorylation P06493 (CDK1)
Y36 Phosphorylation
S42 Phosphorylation
S44 Phosphorylation
R45 Methylation
S47 Phosphorylation
S49 O-Glycosylation
S49 Phosphorylation
R50 Methylation
S51 Phosphorylation
T52 Phosphorylation
S53 Phosphorylation P17252 (PRKCA) , Q9UBS0 (RPS6KB2) , P49137 (MAPKAPK2) , Q02156 (PRKCE) , P51812 (RPS6KA3) , Q14012 (CAMK1) , Q9UQM7 (CAMK2A)
R55 Methylation
S60 Phosphorylation
T65 Phosphorylation
K81 Acetylation
K81 Sumoylation
K81 Ubiquitination
T83 Phosphorylation
S86 Phosphorylation
R90 Methylation
S93 Phosphorylation
Y94 Phosphorylation
R97 Methylation
S100 Phosphorylation
S110 Phosphorylation
K111 Acetylation
K118 Methylation
K118 Ubiquitination
S127 Phosphorylation
Y129 Phosphorylation
K131 Acetylation
K131 Methylation
K131 Ubiquitination
K167 Acetylation
K167 Methylation
K167 Sumoylation
K167 Ubiquitination
Y168 Phosphorylation
S177 Phosphorylation
K187 Acetylation
K187 Methylation
K187 Sumoylation
K187 Ubiquitination
T192 Phosphorylation
T195 Phosphorylation
T201 Phosphorylation
K207 Sumoylation
K207 Ubiquitination
K214 Acetylation
K214 Ubiquitination
K215 Ubiquitination
K222 Acetylation
S230 Phosphorylation
K241 Ubiquitination
S242 Phosphorylation
K247 Acetylation
K247 Sumoylation
K247 Ubiquitination
Y256 Phosphorylation
K262 Ubiquitination
K269 Sumoylation
Y270 Phosphorylation
S272 Phosphorylation
T302 Phosphorylation
S305 Phosphorylation
S312 Phosphorylation
K317 Acetylation
K317 Sumoylation
K317 Ubiquitination
S319 Phosphorylation
S323 Phosphorylation
Y331 Phosphorylation
S347 Phosphorylation
Y363 Phosphorylation
K370 Ubiquitination
K372 Sumoylation
K372 Ubiquitination
T379 Phosphorylation
Y380 Phosphorylation
S398 Phosphorylation
S399 Phosphorylation
S401 Phosphorylation
T404 Phosphorylation
K407 Ubiquitination
T409 Phosphorylation
K417 Acetylation
K417 Sumoylation
K417 Ubiquitination
S420 Phosphorylation
T422 Phosphorylation
T425 Phosphorylation
K426 Acetylation
K426 Methylation
K426 Sumoylation
K426 Ubiquitination

Research Backgrounds

Function:

Involved in the uptake of thrombin-antithrombin complexes by hepatic cells (By similarity). When phosphorylated, plays a role in filament reorganization. Involved in the delivery of mutated CFTR to the plasma membrane. Together with KRT8, is involved in interleukin-6 (IL-6)-mediated barrier protection.

PTMs:

Phosphorylation at Ser-34 increases during mitosis. Hyperphosphorylated at Ser-53 in diseased cirrhosis liver. Phosphorylation increases by IL-6.

Proteolytically cleaved by caspases during epithelial cell apoptosis. Cleavage occurs at Asp-238 by either caspase-3, caspase-6 or caspase-7.

O-GlcNAcylation increases solubility, and decreases stability by inducing proteasomal degradation.

Subcellular Location:

Cytoplasm>Perinuclear region. Nucleus>Nucleolus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in colon, placenta, liver and very weakly in exocervix. Increased expression observed in lymph nodes of breast carcinoma.

Subunit Structure:

Heterotetramer of two type I and two type II keratins. KRT18 associates with KRT8. Interacts with the thrombin-antithrombin complex (By similarity). Interacts with PNN and mutated CFTR. Interacts with YWHAE, YWHAH and YWHAZ only when phosphorylated. Interacts with DNAJB6, TCHP and TRADD. Interacts with FAM83H. Interacts with EPPK1 (By similarity).

(Microbial infection) Interacts with hepatitis C virus/HCV core protein.

Family&Domains:

Belongs to the intermediate filament family.

Research Fields

· Human Diseases > Infectious diseases: Bacterial > Pathogenic Escherichia coli infection.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.